^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug Class:FLT3 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    TCT-ASTCT-CIBMTR 2023
    Title:

    147 - Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study

    Published date:
    12/16/2022
    Excerpt:
    All patients had an AML diagnosis with a FLT3 mutation…Of the 40 patients included in this study, 30 (75%) had the FLT3-ITD mutation, and 10 (25%) had the FLT3-TKD mutation….Post-HSCT maintenance, primarily with gilteritinib, resulted in improved OS and RFS in our patients. Amongst our patients receiving FLT3 inhibitors for maintenance, OS at 24 months was 96.2% and RFS was 89.7%.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SOHO 2021
    Title:

    Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center, Real-World Experience

    Published date:
    09/01/2021
    Excerpt:
    Among the patients who received CCT+FLT3i, CR and OOR were 46% and 93%, respectively….Combination of FLT3i based therapy with CCT is effective therapy in FLT3-ITD frontline patients in a real-world setting.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia

    Published date:
    11/01/2018
    Excerpt:
    Once censored for AlloHCT, achievement of a negative MRD by flow cytometry (p=0.01), CR instead of CRi (p<0.003) and FLT3 inhibitor treatment (p=0.001) demonstrated a significant increase in RFS.
    DOI:
    https://doi.org/10.1182/blood-2018-99-119928
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Bioorg Med Chem Lett
    Title:

    Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors

    Published date:
    09/05/2020
    Excerpt:
    In particular, compound 16b demonstrated significant inhibitory potency against FLT3-ITD (IC50 = 5.60 nM) and better antiproliferative activity than quizartinib against MV4-11 cell line (IC50 = 0.176 nM). It is indicated that compound 16b for the treatment of acute myeloid leukemia could be very promising.
    DOI:
    10.1016/j.bmcl.2020.127525